Zilenta-M Tablet ER

Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, which in turn stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. The extended-release formulation of Zilenta-M ensures a gradual release of active ingredients, promoting better tolerability and adherence by minimizing gastrointestinal side effects commonly associated with Metformin.

This combination therapy is indicated for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve target glycemic levels. Zilenta-M Tablet ER should be used under medical supervision, with regular monitoring of blood glucose and renal function. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to any component.

Dose adjustments may be necessary in hepatic or renal dysfunction. This combination offers a complementary mechanism of action, addressing multiple pathophysiological defects in type 2 diabetes, thereby improving overall glycemic control and reducing the risk of diabetes-related complications.